2 december 2017: Klik op de titel

the phase III JAVELIN Gastric 300 trial did not meet its primary endpoint of superior overall survival with single-agent avelumab (Bavencio) compared with physician's choice of chemotherapy.

The trial investigated avelumab as a third-line treatment for unresectable, recurrent, or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma patients whose disease progressed following two prior therapeutic regimens, regardless of programmed cell death ligand 1 (PD-L1) expression. The safety profile of avelumab was consistent with that observed in the overall JAVELIN clinical development program.

Plaats een reactie ...

Reageer op "Immuuntherapie met avelumab: Update on Phase III JAVELIN Gastric 300 Trial of Avelumab in Pretreated Advanced Gastric Cancer"

Gerelateerde artikelen

Gerelateerde artikelen

Immuuntherapie met avelumab: >> Immuuntherapie met het anti-PD >> Immuuntherapie met nivolumab >> Immuuntherapie bij maagkanker: >>